Clinical Analysis of Matched Sibling Donor Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Young Patients with Multiple Myeloma.
10.19746/j.cnki.issn.1009-2137.2023.02.022
- Author:
Yi-Rui ZHONG
1
;
Li DING
1
;
Xiao-Hua LUO
1
;
Li WANG
1
;
Xiao-Qiong TANG
1
;
Hong-Bin ZHANG
1
;
Qing XIAO
1
;
Lin LIU
2
Author Information
1. Department of Hematology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.
2. Department of Hematology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.E-mail: liulin@cqmu.edu.cn.
- Publication Type:Journal Article
- Keywords:
allogeneic hematopoietic stem cell transplantation;
efficacy;
multiple myeloma
- MeSH:
Humans;
Middle Aged;
Multiple Myeloma;
Siblings;
Retrospective Studies;
Hematopoietic Stem Cell Transplantation/adverse effects*;
Graft vs Host Disease
- From:
Journal of Experimental Hematology
2023;31(2):462-468
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the efficacy and safety of matched sibling donor allogeneic hematopoietic stem cell transplantation (allo-HSCT) in the treatment of young patients with multiple myeloma (MM).
METHODS:The clinical data of 8 young patients (median age：46 years) with MM who underwent allo-HSCT from HLA-indentical sibling donors in the First Affiliated Hospital of Chongqing Medical University from June 2013 to September 2021 were collected, and their survival and prognosis were retrospectively analyzed.
RESULTS:All the patients were successfully transplanted, and 7 patients could be evaluated the efficacy after transplantation. The median follow-up time was 35.2 (2.5-84.70) months. The complete response (CR) rate was 2/8 before transplantation and 6/7 after transplantation. Acute GVHD developed in 2 cases and extensive chronic GVHD developed in 1 case. Within 100 days, 1 case died of non-recurrent events, and 1-year and 2-year disease-free survival were 6 and 5 cases, respectively. At the end of follow-up, all the 5 patients who survived for more than 2 years survived, and the longest disease-free survival time has reached 84 months.
CONCLUSION:With the development of new drugs, HLA-matched sibling donor allo-HSCT may be a curable treatment for young patients with MM.
